Kamada Shares Are Up 10%

Shares of biopharmaceutical company, Kamada Ltd. (KMDA) rose 10% on Wednesday, on news of private placement with FIMI, receiving FDA approval to manufacture CYTOGAM, and being granted marketing authorization for GLASSIA.

KMDA is currently trading at $5.16, up 10.22% or $0.48 per share, on Nasdaq. It has traded between $3.72 and $5.60 in the past 52-week period.

Kamada has entered into a securities purchase agreement with private equity investor FIMI Opportunity Funds (FIMI), to purchase $60 million of its ordinary shares in a private placement.

FDA has approved the application to manufacture CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at the Company's facility in Beit Kama, Israel.

The company has been granted marketing authorization in Switzerland from Swissmedic for GLASSIA, for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary AATD.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT